| Abstract: | OBJECTIVE: To evaluate current evidence on the efficacy and safety of Cordyceps sinensis(cordyceps)or its fermented products used as an adjunctive treatment in patients undergoing maintenance hemodialysis.METHODS: The Cochrane Central Register of Controlled Trials(CENTRAL), EMBASE, MEDLINE, China National Knowledge Infrastructure(CNKI) and Wanfang Database were searched for relevant randomized controlled trials up to March 2016. Two review authors independently selected trials for inclusion,extracted data, assessed the methodological quality and rated the quality of evidence with the Grading of Recommendations, Assessment, Development and Evaluation approach.RESULTS: Twelve studies involving 655 participants were included. Evidence of low to moderate-quality showed that cordyceps plus conventional treatment compared to conventional treatment alone significantly improved C-reactive protein [standardized mean difference(SMD)-0.61; 95% confi-dence intervals(CI)-1.00 to-0.22], high-sensitivity C-reactive protein [weighted mean difference(WMD)-3.44 mg/L; 95% CI-3.89 to-2.99], serum albumin(WMD 3.07 g/L; 95% CI 1.59 to 4.55),malondialdehyde(WMD-1.95 nmol/L; 95% CI-2.24 to-1.66), and hemoglobin(WMD 9.56 g/L;95% CI 3.65 to 15.47) levels. However, there was no significant improvement for serum creatinine and low-density lipoprotein cholesterol. Overall, most trials either did not monitor adverse events or poorly documented them.CONCLUSION: Given the small number of trials included, the unclear methodological quality of the included trials, and the high heterogeneity in pooled analyses, the evidence obtained in this review is insufficient to recommend the use of cordyceps as adjunctive treatment in hemodialysis patients. |
